The effects of low-dose growth hormone in HIV-infected men with fat accumulation: A pilot study

Clinical Infectious Diseases

Volumn 39, Issue 5, 2004, Pages 732-735

  Lo, Joan C ^a,b   Mulligan, Kathleen ^a,b   Noor, Mustafa A ^a,c,f   Lee, Grace A ^a,c   Schwarz, Jean Marc ^a,b,d,e   Grunfeld, Carl ^a,c   Schambelan, Morris ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Touro University California   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; CHORIONIC GONADOTROPIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GEMFIBROZIL; GROWTH HORMONE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NICOTINIC ACID; RITONAVIR; STAVUDINE; TESTOSTERONE; ZIDOVUDINE;

ADULT; ARTHRALGIA; ARTICLE; BODY FAT; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; GLUCOSE TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; INSULIN SENSITIVITY; KAPOSI SARCOMA; LEAN BODY WEIGHT; LIPID STORAGE; LOW DRUG DOSE; MALE; PILOT STUDY; PRIORITY JOURNAL;

ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; GROWTH HORMONE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 4444377513     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422725     Document Type: Article

References (15)

1. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351:867-70.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-5.
3. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14:37-49.
4. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002; 113:229-32.
5. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36:909-16.
6. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-36.
7. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86:3480-7.
8. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002; 87:942.
9. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13:2099-103.
10. Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002; 30:379-91.
11. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:239-52.
12. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-23.
13. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988; 37:287-301.
14. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82:727-34.
15. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 2002; 35:1258-62.